[go: up one dir, main page]

SI2051706T1 - Transmukozna aplikacija 2-(10-hidroksidecil)-5,6-dimetoksi-3-metil-2,5- cikloheksadien-1,4-diona (idebenona) - Google Patents

Transmukozna aplikacija 2-(10-hidroksidecil)-5,6-dimetoksi-3-metil-2,5- cikloheksadien-1,4-diona (idebenona)

Info

Publication number
SI2051706T1
SI2051706T1 SI200731778A SI200731778A SI2051706T1 SI 2051706 T1 SI2051706 T1 SI 2051706T1 SI 200731778 A SI200731778 A SI 200731778A SI 200731778 A SI200731778 A SI 200731778A SI 2051706 T1 SI2051706 T1 SI 2051706T1
Authority
SI
Slovenia
Prior art keywords
idebenone
hydroxydecyl
cyclohexadiene
dione
dimethoxy
Prior art date
Application number
SI200731778A
Other languages
English (en)
Inventor
Judith Dubach-Powell
Rudolf Hausmann
Pierre Vancan
Original Assignee
Santhera Pharmaceuticals (Schweiz) Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals (Schweiz) Ag filed Critical Santhera Pharmaceuticals (Schweiz) Ag
Publication of SI2051706T1 publication Critical patent/SI2051706T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731778A 2006-08-14 2007-08-03 Transmukozna aplikacija 2-(10-hidroksidecil)-5,6-dimetoksi-3-metil-2,5- cikloheksadien-1,4-diona (idebenona) SI2051706T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83749606P 2006-08-14 2006-08-14
EP06016935A EP1891946A1 (en) 2006-08-14 2006-08-14 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
PCT/EP2007/006895 WO2008019769A1 (en) 2006-08-14 2007-08-03 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10- hydroxydecy l)-1,4-benzoquinone
EP07801511.2A EP2051706B1 (en) 2006-08-14 2007-08-03 Transmucosal administration of 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione (idebenone)

Publications (1)

Publication Number Publication Date
SI2051706T1 true SI2051706T1 (sl) 2016-06-30

Family

ID=37564291

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731778A SI2051706T1 (sl) 2006-08-14 2007-08-03 Transmukozna aplikacija 2-(10-hidroksidecil)-5,6-dimetoksi-3-metil-2,5- cikloheksadien-1,4-diona (idebenona)

Country Status (19)

Country Link
US (1) US20090208425A1 (sl)
EP (2) EP1891946A1 (sl)
JP (2) JP5665167B2 (sl)
CN (1) CN101541317B (sl)
AU (1) AU2007286491B2 (sl)
BR (1) BRPI0715901A2 (sl)
CA (1) CA2660577C (sl)
CY (1) CY1117860T1 (sl)
ES (1) ES2574087T3 (sl)
HU (1) HUE029241T2 (sl)
IL (1) IL196745A (sl)
MX (1) MX2009001674A (sl)
NZ (1) NZ574422A (sl)
PL (1) PL2051706T3 (sl)
PT (1) PT2051706T (sl)
RU (1) RU2429830C2 (sl)
SI (1) SI2051706T1 (sl)
WO (1) WO2008019769A1 (sl)
ZA (1) ZA200900902B (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2108366B1 (en) 2008-04-09 2011-10-19 Santhera Pharmaceuticals (Schweiz) AG Idebenone for the treatment of respiratory illness in muscular dystrophy
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
RS55173B1 (sr) 2010-08-16 2017-01-31 Santhera Pharmaceuticals (Schweiz) Ag Uređaj i sistem za proizvodnju aerosola sa poboljšanim protokom vazduha
CN102091038B (zh) * 2011-01-20 2012-07-25 天津大学 艾地苯醌纳米脂质载体透皮吸收制剂及制备方法
US10806703B2 (en) 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
EP2620141A1 (en) 2012-01-25 2013-07-31 Santhera Pharmaceuticals (Schweiz) AG Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
US20150150790A1 (en) * 2013-12-04 2015-06-04 Jao Hung Biotechnology Co., Ltd. Transdermal enhancer
DE102017104277A1 (de) 2017-03-01 2018-09-06 Lts Lohmann Therapie-Systeme Ag Transmukosales Verabreichungssystem für Idebenon
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
EP4121023A1 (en) 2020-03-19 2023-01-25 Bemido SA Idebenone for the treatment of acute respiratory distress syndrome (ards) in patients diagnosed with a coronavirus infection
EP4351545A1 (en) 2021-06-07 2024-04-17 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy
CN115944599B (zh) * 2023-01-17 2025-09-02 中国药科大学 一种艾地苯醌滴丸及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2503571B2 (ja) * 1988-02-26 1996-06-05 武田薬品工業株式会社 脳循環代謝改善剤
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
EP0915696B1 (en) * 1996-07-11 2002-05-29 Takeda Chemical Industries, Ltd. ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION
JPH11116470A (ja) * 1997-08-12 1999-04-27 Takeda Chem Ind Ltd イデベノン含有経皮投与製剤
WO1999015210A2 (en) * 1997-09-26 1999-04-01 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
CA2381860C (en) * 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
RU2168985C1 (ru) * 2000-09-06 2001-06-20 Федеральное государственное унитарное предприятие Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко Лекарственные формы ноотропного средства (варианты) и способ их получения
EP1388340B1 (en) * 2001-05-10 2010-09-08 Kaneka Corporation Compositions for transmucosal administration containing coenzyme q as the active ingredient
JP2003026567A (ja) * 2001-05-10 2003-01-29 Kanegafuchi Chem Ind Co Ltd 補酵素ｑを有効成分とする粘膜投与用組成物
RU2201711C2 (ru) * 2001-06-27 2003-04-10 Московский научно-исследовательский институт психиатрии Способ оценки эффективности терапии идебеноном когнитивных нарушений
MXPA03000985A (es) * 2001-07-27 2004-04-02 Yamanouchi Pharma Co Ltd Composicion que comprende particulas finas de liberacion sostenida para tabletas de desintegracion rapida en la cavidad bucal y metodo de fabricacion de la misma.
DE60211875T2 (de) * 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
AU2005209706A1 (en) * 2004-10-07 2006-04-27 Kabushiki Kaisha Sangi Transdermal and transmucosal preparations
DK1861080T3 (da) * 2005-03-21 2010-09-06 Santhera Pharmaceuticals Ch Idebenon til behandling af muskeldystrofier

Also Published As

Publication number Publication date
CN101541317A (zh) 2009-09-23
WO2008019769A1 (en) 2008-02-21
JP5665167B2 (ja) 2015-02-04
HUE029241T2 (en) 2017-02-28
JP2013100319A (ja) 2013-05-23
AU2007286491A1 (en) 2008-02-21
CA2660577C (en) 2012-05-01
BRPI0715901A2 (pt) 2013-08-06
US20090208425A1 (en) 2009-08-20
EP1891946A1 (en) 2008-02-27
ES2574087T3 (es) 2016-06-14
AU2007286491B2 (en) 2010-06-24
ZA200900902B (en) 2010-07-28
MX2009001674A (es) 2009-02-25
EP2051706A1 (en) 2009-04-29
CY1117860T1 (el) 2017-05-17
RU2009103638A (ru) 2010-09-27
NZ574422A (en) 2011-04-29
CN101541317B (zh) 2015-04-15
IL196745A (en) 2016-10-31
PL2051706T3 (pl) 2016-11-30
JP5907901B2 (ja) 2016-04-26
CA2660577A1 (en) 2008-02-21
PT2051706T (pt) 2016-07-18
JP2010500384A (ja) 2010-01-07
RU2429830C2 (ru) 2011-09-27
IL196745A0 (en) 2009-11-18
EP2051706B1 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
PT2051706T (pt) Administração por via transmucosa de 2-(10-hidroxidecil)-5,6-dimetoxi-3-metil-2,5-ciclo-hexanodieno-1,4-diona (idebenona)
HUS2000031I1 (hu) Benzimidazol-származékok
GB2450002B (en) Semiconductor electrochemical sensors
PL2171173T3 (pl) Sposób i urządzenie do zbierania papieru podkładowego do płyty gipsowej
EP2170085A4 (en) INSECT REPELLENT FORMULATIONS
GB2487326B (en) Measurement of the mobility of mass-selected ions
EP2212230A4 (en) LIFT
EP2135075B8 (en) Whole blood assay
EG25382A (en) Use of tocopherol.
IL196200A0 (en) Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin-10,10-dioxide
EP2250145A4 (en) PREPARATION OF NAPHTHOCHINONE COMPOUNDS USING 2,3-DIHALONAPHOCHINONE
EP2294049A4 (en) ORAL ACTIVE CURCUMINOID COMPOUNDS
GB2451150B (en) Lifts
PL383170A1 (pl) Sposób otrzymywania preparatu wapniowego
Yun Union is Strength
PL381659A1 (pl) Sposób otrzymywania tosylanu 1,3-bis(1,4-anhydro-2,3- O-izopropylideno-5- deoksy D,L-rybitol-5-ilo) imidazol-3-iowego
PL385928A1 (pl) Nowe podstawione 1,3-bis( styrylo)tetrametylodisiloksany, oraz sposób otrzymywania podstawionych 1,3-bis(styrylo)tetrametylodisiloksanów
PH32008000748S1 (en) Tablet of chocolate, new wing (col)
GB0703109D0 (en) Encapsulation of feeds
PL383291A1 (pl) Sposób otrzymywania okta (halogenoalkilo) oktasilseskwioksanów
GB0703126D0 (en) Lift measurement
GB0701542D0 (en) Zakia elevator/luxator
HK1159610A (en) Processes for the preparation of bendamustine
GB0700602D0 (en) Easy-p (urinal bottle)
PL383981A1 (pl) Sposób pomiaru, zwłaszcza pola powierzchni i układ do pomiaru, zwłaszcza pola powierzchni